US 12,292,449 B2
Device and method for detection of analytes
Leah Amir, St. Louis, MO (US); and Gary Anderson, St. Louis, MO (US)
Assigned to Xcellcure, LLC, St. Louis, MO (US)
Filed by Xcellcure, LLC, St. Louis, MO (US)
Filed on Sep. 26, 2023, as Appl. No. 18/372,933.
Application 15/920,076 is a division of application No. 14/388,164, granted, now 9,958,457, issued on May 1, 2018, previously published as PCT/US2013/033916, filed on Mar. 26, 2013.
Application 18/372,933 is a continuation of application No. 16/750,807, filed on Jan. 23, 2020, granted, now 11,802,880.
Application 16/750,807 is a continuation of application No. 15/920,076, filed on Mar. 13, 2018, granted, now 10,564,166, issued on Feb. 18, 2020.
Claims priority of provisional application 61/790,686, filed on Mar. 15, 2013.
Claims priority of provisional application 61/615,599, filed on Mar. 26, 2012.
Prior Publication US 2024/0019445 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); C12Q 1/6883 (2018.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/6863 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/543 (2013.01); G01N 33/6893 (2013.01); G01N 2800/324 (2013.01); G01N 2800/325 (2013.01); G01N 2800/50 (2013.01)] 20 Claims
 
1. A method for predicting a cardiac failure in a subject, the method comprising:
a. collecting a biological sample from the subject;
b. contacting a device with the biological sample, the device comprising:
i) a surface to conduct at least one detection reaction, the surface comprising:
a detection region comprising one or more epitope binding agents, wherein each epitope binding agent is configured to bind exclusively to at least one analyte; and
a reference region, wherein the detection region is separate from the reference region;
ii) one or more detection sensors to sense light associated with the detection region;
iii) one or more reference sensors to sense light associated with the reference region;
wherein the one or more detection sensors and the one or more reference sensors are operated using a balanced sensor method, and wherein the detection region of the device comprises epitope binding agents specific for at least four biomarkers in the biological sample, the at least four biomarkers being selected from the group consisting of MIP 1 alpha (CCL3) (macrophage inflammatory protein 1α, chemokine C-C motif ligand 3), RANTES (CCL5)(Regulated upon Activation, Normal T-cell Expressed, and Secreted, chemokine (C-C motif) ligand 5), CCL18(chemokine (C-C motif) ligand 18 cytokine), HFABP (Heart-type Fatty Acid-Binding Protein), PAPPA (Pregnancy-associated Plasma Protein A), hsCRP (C-reactive protein), hs cTnl (cardiac Troponin I), PIGF (Placental growth factor), Nt-proBNP(brain natriuretic peptide), IP-10(Interferon gamma-induced protein 10), MIC-1(macrophage inhibitory cytokine 1), cystatin C, LP PLA2(lipoprotein-associated phospholipase);
c. detecting with the device whether the level of an analyte was in a positive range associated with cardiac failure; and
d. identifying the subject as at risk for future cardiac failure when one or more of the analytes in the biological sample are in the positive range.